Stoke Therapeutics, Inc. · NASDAQ:STOK

Stoke Therapeutics — 36th International Epilepsy Congress (August 2025)

9 slides from Stoke Therapeutics's conference presentation, Aug 31, 2025

  1. Slide 1: Zorevunersen demonstrates potential as a disease-modifying therapy in Dravet syndrome

    Zorevunersen demonstrates potential as a disease-modifying therapy in patients with Dravet syndrome through durable seizure reduction and improvements in cognition, behavior, and functioning with up to 36 months of maintenance dosing in open-label extension studies 36th International Epilepsy Congre

  2. Slide 2: Speaker disclosures

    Speaker disclosures • Received honoraria for presenting at educational events and advisory boards • Consultancy work for Biocodex, GW / Jazz Pharma, Encoded Therapeutics, Servier, Stoke Therapeutics, and Zogenix/UCB 2

  3. Slide 3: Dravet syndrome is a severe developmental and epileptic encephalopathy with a burdensome treatment paradigm

    Dravet syndrome is a severe developmental and epileptic encephalopathy with a burdensome and challenging treatment paradigm1 About 85% of DS cases are caused by SCN1A gene variants that result in 50% NaV1.1 sodium channel expression2–4 Despite being on currently Results from the BUTTERFLY 24-month n

  4. Slide 4: Safety, pharmacokinetics, and effectiveness evaluated in Phase 1/2a and OLE studies

    Safety, pharmacokinetics, and effectiveness of zorevunersen in children and adolescents were evaluated in Phase 1/2a and OLE studies ELIGIBILITY CRITERIA MONARCH and ADMIRAL SWALLOWTAIL and LONGWING • 2–18 years of age Phase 1/2a studies OLE studies (ongoing) • Established DS diagnosis DOSES STUDY L

  5. Slide 5: Reductions in convulsive seizure frequency were maintained through 3 years

    Reductions in convulsive seizure frequency were maintained through 3 years of treatment with zorevunersen on top of standard of care in the OLE studies Change in convulsive seizure frequency for all patients in the OLEs separated by dose received in the Ph1/2a studies in convulsive seizure frequency

  6. Slide 6: Substantial improvements in cognition and behavior continued through 3 years

    Substantial improvements in cognition and behavior continued through 3 years of treatment with zorevunersen in the OLE studies Change in Vineland-3 subdomain raw scores at 12, 24, and 36 months compared to OLE baseline 3.2 Expressive Communication 6.9 Month 12 (n=66) 7.6 2.4 Month 24 (n=44) Receptiv

  7. Slide 7: Substantial improvements in quality of life continued through 3 years

    Substantial improvements in quality of life continued through 3 years of treatment with zorevunersen in the OLE studies Change in EQ-VAS scores at 12, 24, and 36 months compared to OLE baseline 30 LS mean change in EQ-VAS score 25 Improving from OLE baseline (95% CI) 18.0 20 11.9 15 10 1.9 5 0 Month

  8. Slide 8: Zorevunersen was generally well tolerated with long-term dosing

    Zorevunersen was generally well tolerated with long-term dosing • 30% of patients experienced a study drug–related TEAE Phase 1/2a o Most common: CSF protein elevations (14%) and procedural vomiting (5%) studies • 22% of patients experienced a TESAE (n=81) o All were unrelated to the study drug exce

  9. Slide 9: OLE study findings support zorevunersen as a durable, disease-modifying therapy

    OLE study findings support the potential of zorevunersen as a durable, disease-modifying therapy for patients with Dravet syndrome • Patients already receiving best-available ASMs experienced substantial reductions in convulsive seizure frequency upon treatment with zorevunersen • Overall, durable r

Stoke Therapeutics — 36th International Epilepsy Congress (August 2025) on 6ix